RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:99925

Invasive mole

low confidenceDisorder

Publications

1,558

Trials

1

Interventional, condition-specific

Researchers

1,013

Distinct authors in sample

Gene link

—

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A form of gestational trophoblastic neoplasia similar to a hydatidiform mole but with deep invasion into the myometrium and histologically characterized by hyperplasia of trophoblasts, generalized cystic degeneration of chorionic villi and the presence of molar villi in the myometrium and/ or uterine blood vessels. Indicative signs include persistent unexplained metrorrhagia or secondary increase, stagnation, or non-normalization at 6 months of total serum chorionic gonadotropin (hCG) levels after evacuation of a hydatidiform mole. Metastases (in the lungs or vagina) may be observed.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (7)

chorioadenoma · chorioadenoma Destruens · chorioadenoma destruens · invasive Mole · invasive gestational trophoblastic neoplasm · invasive hydatidiform Mole · invasive hydatidiform mole

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    1,558 matched papers (639 in last 10 years) Source

  3. Phenotype characterisedPresent

    1 HPO annotations (e.g. Menometrorrhagia) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    1 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

1

Associated phenotypes · MONDO:0020549

  • Menometrorrhagia

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

1,558

1,558 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

1,558 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

639 in the last 10 years · low confidence

Phrase hits: 1,557 · MeSH hits: 5

Open Europe PMC search

Who's working on it?

1,013

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Chen L5 papers · 2023

    Department of Gynecology, Zhu Zhou Central Hospital, Zhuzhou, China.

    Papers in Europe PMC
  2. 02
    Niimi K5 papers · 2026

    Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

    Papers in Europe PMC
  3. 03
    Sun SY5 papers · 2026

    Department of Obstetrics, Universidade Federal de Sao Paulo - UNIFESP, Escola Paulista de Mediina, Sao Paulo, Brazil.

    Papers in Europe PMC
  4. 04
    Yamamoto E5 papers · 2026

    Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan.

    Papers in Europe PMC
  5. 05
    Braga A4 papers · 2026

    Universidade Federal do Rio de Janeiro Rio de JaneiroRJ Brazil Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.

    Papers in Europe PMC
  6. 06
    Harsono AB4 papers · 2026

    Department of Obstetrics and Gynecology, Faculty of Medicine, Padjadjaran University, Dr Hasan Sadikin General Hospital Bandung, Bandung, West Java, Indonesia.

    Papers in Europe PMC
  7. 07
    Kajiyama H4 papers · 2026

    Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.

    Papers in Europe PMC
  8. 08
    Nishino K4 papers · 2025

    Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

    Papers in Europe PMC
  9. 09
    Winarno GNA4 papers · 2026

    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Padjadjaran University, Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.

    Papers in Europe PMC
  10. 10
    Berkowitz RS3 papers · 2026

    New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

1

interventional trials for this specific condition

1 interventional trial matched this specific condition name; none in our sample are currently recruiting.

Data as of 11 September 2026

1 interventional trial — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 80.1th percentile).

low confidence · 80.1th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

1 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 2 · after dedupe 2 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 2 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (2)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Invasive mole — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Invasive mole" OR "chorioadenoma" OR "chorioadenoma Destruens" OR "invasive gestational trophoblastic neoplasm" OR "invasive hydatidiform Mole"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Hydatidiform Mole, Invasive

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Invasive mole" OR "chorioadenoma" OR "chorioadenoma Destruens" OR "invasive gestational trophoblastic neoplasm" OR "invasive hydatidiform Mole" OR "Hydatidiform Mole, Invasive"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 1 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (1558) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T06:40:14.422Z